

Special Issue

Recent Research on Neutralizing Antibody Response to SARS-CoV-2 Variants

Message from the Guest Editor

COVID-19 continues to spread globally. Despite vaccination boosting, the risk of getting infected or reinfected with SARS-CoV-2 remains due to the emergence of viral variants. Often, these variants may evade naturally acquired or vaccine-induced immunity. Therefore, it is essential to study the relationship between genetic diversity, antibody response, and the evolution of SARS-CoV-2. The aim of this Special Issue is to evaluate recent research on the neutralizing antibody response to SARS-CoV-2 variants. We welcome original research articles and reviews. Research areas may include but are not limited to SARS-CoV-2 and vaccines, SARS-CoV-2 and natural infection, immunity mechanisms, competition between variants, vaccine escape, and SARS-CoV-2 dynamics. We look forward to receiving your contributions.

Guest Editor

Dr. Chloé Dimeglio

Virology Laboratory, Toulouse University Hospital, 31300 Toulouse, France

Deadline for manuscript submissions

closed (6 August 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/198626

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).